Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Aug;54(8):1194-202.
doi: 10.1136/gut.2004.062745.

Chemoradiotherapy for colorectal cancer

N Andre  1 , W Schmiegel
Affiliations
Review

Chemoradiotherapy for colorectal cancer

N Andre et al. Gut. 2005 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time points for clinical introduction of systemic treatments and treatment strategies in colorectal cancer. 5-FU, 5- fluorouracil.
Figure 2
Figure 2
A 62 year old patient with rectal cancer. (A) Rectoscopic image of endoluminal tumour. (B) Endoscopic ultrasound showing invasion through the muscularis propria (T3). (C) Schematic view of the mucosal layers and staging patterns.
Figure 3
Figure 3
Median overall survival (mOS) correlates with the number of applied substances. Adapted from Grothey et al 2004. 5-FU, 5- fluorouracil; LV inf, leucovorin infusion.
Figure 4
Figure 4
A 54 year old patient with advanced cancer of the ascending colon. (A) Multiple liver metastasis at first diagnosis. (B) Regression after four months of FOLFOX4 (oxaliplatin, infusional fluorouracil, and leucovorin) + bevacizumab.
Figure 5
Figure 5
Schematic overview of target structures for monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI). (A) MAbs bind to soluble ligand and thereby inhibit receptor activation (for example, bevacizumab). (B) MAbs block the ligand binding site at the receptor (for example, cetuximab). (C) TKI bind to the catalytic area of the intracellular kinase domain (for example, erlotinib, gefitinib).
Figure 6
Figure 6
(A) Overall survival data from randomised phase III firstline trials. (B) Estimated costs for firstline systemic therapy in advanced colorectal cancer. Costs are calculated for a treatment course of eight weeks (patient 75 kg/175 cm) in US dollars. 5-FU, 5- fluorouracil; LV, leucovorin; IFL, irinotecan, fluorouracil, and leucovorin; FOLFIRI, irinotecan, infusional fluorouracil, and leucovorin; FOLFOX, oxaliplatin, infusional fluorouracil, and leucovorin.
See this image and copyright information in PMC

References

    1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481–8. - PubMed
    1. Russo MW, Wei JT, Thiny MT, et al. Digestive and liver diseases statistics, 2004. Gastroenterology 2004;126:1448–53. - PubMed
    1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30. - PubMed
    1. Abulafi AM. Williams NSLocal recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994;81:7–19. - PubMed
    1. Faivre-Finn C, Bouvier AM, Mitry E, et al. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? Aliment Pharmacol Ther 2002;16:353–9. - PubMed

MeSH terms